All In Biotech

Drug Trial Radar · NCT03781414

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Two Regimens of Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additionalr Follow-up and a Long-term Extension (CONTRAIL I)

Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

129

Actual

Start

Oct 7, 2019

Primary completion

Apr 20, 2023

Study completion Apr 20, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.

Conditions

  • Liver Transplant Rejection

Interventions

  • CFZ533Biological

    Comparison with standard of care immunosuppression

  • Tacrolimus - MMF - corticosteroidsDrug

    Standard of care immunosuppresive regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Composite Event (Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death) Over 12 MonthsTime frame: Baseline to Month 12

Locations

29 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • University of Colorado Hospital - Aurora

    Aurora, Colorado

  • Northwestern University

    Chicago, Illinois

  • Henry Ford Hospital

    Detroit, Michigan

  • Wash U School of Medicine

    St Louis, Missouri

  • Duke Univ Medical Center

    Durham, North Carolina

  • University Of Cincinnati

    Cincinnati, Ohio

  • Medical University of South Carolina MUSC

    Charleston, South Carolina

  • The Methodist Hospital

    Houston, Texas

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Chambray-lès-Tours, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Pisa, PI, Italy

  • Novartis Investigative Site

    Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Seville, Andalusia, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.